{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T09:03:47Z","timestamp":1770714227647,"version":"3.49.0"},"reference-count":128,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Thymic tumors are exceedingly rare, and most available treatment data come from pooled retrospective analyses. The cornerstone of management is resection, with the use of systemic therapy and radiation therapy (RT) as tools to facilitate surgery and prevent recurrence, or as primary management in unresectable or metastatic disease. Despite the challenges of managing such rare entities, a number of advances have occurred in surgical techniques, systemic therapy, and RT indications and technologies. There is a growing shift toward minimally invasive surgical techniques and the use of surgery to treat pleural metastases, the most common site of recurrence in thymic tumors. Systemic therapy options now include targeted therapies and immunotherapy. RT continues to evolve as new data clarify postoperative recurrence risks and as more targeted treatment approaches become available. Achieving optimal outcomes relies on multidisciplinary care that thoughtfully individualizes and integrates multimodality treatments.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7077","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:46:24Z","timestamp":1770644784000},"source":"Crossref","is-referenced-by-count":0,"title":["Emerging Strategies in the Management of Thymomas and Thymic Carcinomas"],"prefix":"10.6004","volume":"24","author":[{"given":"Sahar A.","family":"Saddoughi","sequence":"first","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya A.","family":"Alwatari","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian R.","family":"Molina","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology, Department of Medical Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Owen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Front Oncol","first-page":"1308989.","article-title":"Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019","volume":"13","author":"Gerber TS","year":"2023","unstructured":"Gerber TS, Strobl S, Marx A,  Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019. Front Oncol 2023;13:1308989."},{"key":"B2","series-title":"Chest","first-page":"2893","article-title":"Tumors of the mediastinum","volume":"128","author":"Duwe BV","year":"2005","unstructured":"Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest 2005;128:2893\u20132909."},{"key":"B3","series-title":"Ann Thorac Surg","first-page":"975","article-title":"The Society of Thoracic Surgeons expert consensus document on the surgical management of thymomas","volume":"118","author":"Liou DZ","year":"2024","unstructured":"Liou DZ, Berry MF, Brown LM,  The Society of Thoracic Surgeons expert consensus document on the surgical management of thymomas. Ann Thorac Surg 2024;118:975\u20131004."},{"key":"B4","series-title":"Ann Cardiothorac Surg","first-page":"1","article-title":"Minimally invasive versus open thymectomy: a systematic review of surgical techniques, patient demographics, and perioperative outcomes","volume":"5","author":"Hess NR","year":"2016","unstructured":"Hess NR, Sarkaria IS, Pennathur A,  Minimally invasive versus open thymectomy: a systematic review of surgical techniques, patient demographics, and perioperative outcomes. Ann Cardiothorac Surg 2016;5:1\u20139."},{"key":"B5","series-title":"J Thorac Cardiovasc Surg","first-page":"555","article-title":"A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma","volume":"160","author":"Yang CJ","year":"2020","unstructured":"Yang CJ, Hurd J, Shah SA,  A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma. J Thorac Cardiovasc Surg 2020;160:555\u2013567.e15."},{"key":"B6","series-title":"Thorac Cancer","first-page":"151","article-title":"Robot-assisted thoracic surgery versus video-assisted thoracic surgery for treatment of patients with thymoma: a systematic review and meta-analysis","volume":"13","author":"Shen C","year":"2022","unstructured":"Shen C, Li J, Li J, Che G. Robot-assisted thoracic surgery versus video-assisted thoracic surgery for treatment of patients with thymoma: a systematic review and meta-analysis. Thorac Cancer 2022;13:151\u2013161."},{"key":"B7","series-title":"J Clin Med","article-title":"Robotic vs. transsternal thymectomy: a single center experience over 10 years","volume":"10","author":"Azenha LF","year":"2021","unstructured":"Azenha LF, Deckarm R, Minervini F,  Robotic vs. transsternal thymectomy: a single center experience over 10 years. J Clin Med 2021;10:4991."},{"key":"B8","series-title":"Eur J Cardiothorac Surg","first-page":"i34","article-title":"Subxiphoid approach for robotic single-site-assisted thymectomy","volume":"58","author":"Park SY","year":"2020","unstructured":"Park SY, Han KN, Hong JI,  Subxiphoid approach for robotic single-site-assisted thymectomy. Eur J Cardiothorac Surg 2020;58:i34\u201338."},{"key":"B9","series-title":"Eur J Cardiothorac Surg","article-title":"Initial experience with the da Vinci single-port system in patients with an anterior mediastinal mass","volume":"66","author":"Kim IH","year":"2024","unstructured":"Kim IH, Kim YH, Yun JK, Kim HR. Initial experience with the da Vinci single-port system in patients with an anterior mediastinal mass. Eur J Cardiothorac Surg 2024;66:ezae325."},{"key":"B10","series-title":"Surg Endosc","first-page":"4814","article-title":"Da Vinci single-port robotic system current application and future perspective in general surgery: a scoping review","volume":"38","author":"Celotto F","year":"2024","unstructured":"Celotto F, Ramacciotti N, Mangano A,  Da Vinci single-port robotic system current application and future perspective in general surgery: a scoping review. Surg Endosc 2024;38:4814\u20134830."},{"key":"B11","series-title":"Ann Cardiothorac Surg","first-page":"110","article-title":"Biportal robotic surgery for anterior mediastinal mass","volume":"12","author":"Hong JI","year":"2023","unstructured":"Hong JI, Lee JH, Kim HK. Biportal robotic surgery for anterior mediastinal mass. Ann Cardiothorac Surg 2023;12:110\u2013116."},{"key":"B12","series-title":"Mediastinum","first-page":"14.","article-title":"The role of surgery in the management of locally advanced and metastatic thymoma: a narrative review","volume":"5","author":"Wagner C","year":"2021","unstructured":"Wagner C, Wakeam E, Keshavjee S. The role of surgery in the management of locally advanced and metastatic thymoma: a narrative review. Mediastinum 2021;5:14."},{"key":"B13","series-title":"Eur J Cardiothorac Surg","first-page":"346","article-title":"Surgical therapy of thymic tumours with pleural involvement: an ESTS Thymic Working Group Project","volume":"52","author":"Moser B","year":"2017","unstructured":"Moser B, Fadel E, Fabre D,  Surgical therapy of thymic tumours with pleural involvement: an ESTS Thymic Working Group Project. Eur J Cardiothorac Surg 2017;52:346\u2013355."},{"key":"B14","series-title":"J Surg Oncol","first-page":"604","article-title":"Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease","volume":"128","author":"Miller DL","year":"2023","unstructured":"Miller DL, Parks CS, Ange B,  Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease. J Surg Oncol 2023;128:604\u2013611."},{"key":"B15","series-title":"Ann Thorac Surg","first-page":"748","article-title":"A meta-analysis of surgical versus nonsurgical management of recurrent thymoma","volume":"98","author":"Hamaji M","year":"2014","unstructured":"Hamaji M, Ali SO, Burt BM. A meta-analysis of surgical versus nonsurgical management of recurrent thymoma. Ann Thorac Surg 2014;98:748\u2013755."},{"key":"B16","series-title":"Lung Cancer","first-page":"107214","article-title":"Unradical surgery for locally-advanced thymoma: is it time to evolve perspectives?","volume":"180","author":"Mastromarino MG","year":"2023","unstructured":"Mastromarino MG, Bacchin D, Aprile V,  Unradical surgery for locally-advanced thymoma: is it time to evolve perspectives? Lung Cancer 2023;180:107214."},{"key":"B17","series-title":"Thorac Cardiovasc Surg","first-page":"440","article-title":"Debulking surgery plus radiation: treatment choice for unresectable stage III thymic carcinoma","volume":"68","author":"Zhai Y","year":"2020","unstructured":"Zhai Y, Hui Z, Gao Y,  Debulking surgery plus radiation: treatment choice for unresectable stage III thymic carcinoma. Thorac Cardiovasc Surg 2020;68:440\u2013445."},{"key":"B18","series-title":"Sci Rep","first-page":"1735.","article-title":"Impact of definitive radiotherapy and surgical debulking on treatment outcome and prognosis for locally advanced Masaoka-Koga stage III thymoma","volume":"10","author":"Fan C","year":"2020","unstructured":"Fan C, Ge H, Zhang S,  Impact of definitive radiotherapy and surgical debulking on treatment outcome and prognosis for locally advanced Masaoka-Koga stage III thymoma. Sci Rep 2020;10:1735."},{"key":"B19","series-title":"Cancer Cell","first-page":"244","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich M","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I,  The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018;33:244\u2013258.e10."},{"key":"B20","series-title":"Med","first-page":"100612.","article-title":"Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors","author":"Mohrmann L","year":"2025;6","unstructured":"Mohrmann L, Rostock L, Werner M,  Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. Med 2025;6:100612."},{"key":"B21","series-title":"J Clin Oncol","first-page":"814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone G","year":"1996","unstructured":"Giaccone G, Ardizzoni A, Kirkpatrick A,  Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14:814\u2013820."},{"key":"B22","series-title":"J Clin Oncol","first-page":"2060","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma GL","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC,  Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011;29:2060\u20132065."},{"key":"B23","series-title":"Lung Cancer","first-page":"369","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim ES","year":"2004","unstructured":"Kim ES, Putnam JB, Komaki R,  Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369\u2013379."},{"key":"B24","series-title":"Cancer","first-page":"30","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero A","year":"1991","unstructured":"Fornasiero A, Daniele O, Ghiotto C,  Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68:30\u201333."},{"key":"B25","series-title":"Cancer","first-page":"2010","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an Intergroup trial","volume":"91","author":"Loehrer PJ","year":"2001","unstructured":"Loehrer PJ, Jiroutek M, Aisner S,  Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an Intergroup trial. Cancer 2001;91:2010\u20132015."},{"key":"B26","series-title":"Ann Oncol","first-page":"817","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto C","year":"2024","unstructured":"Proto C, Ganzinelli M, Manglaviti S,  Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). Ann Oncol 2024;35:817\u2013826."},{"key":"B27","series-title":"J Clin Oncol","first-page":"1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer PJ","year":"1994","unstructured":"Loehrer PJ, Kim K, Aisner SC,  Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994;12:1164\u20131168."},{"key":"B28","series-title":"Cancer Med","first-page":"3445","article-title":"Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens","volume":"11","author":"Ma WL","year":"2022","unstructured":"Ma WL, Lin CC, Hsu FM,  Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens. Cancer Med 2022;11:3445\u20133456."},{"key":"B29","series-title":"J Thorac Oncol","first-page":"223","article-title":"A phase 2 study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21)","volume":"18","author":"Jung HA","year":"2023","unstructured":"Jung HA, Kim M, Kim HS,  A phase 2 study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21). J Thorac Oncol 2023;18:223\u2013231."},{"key":"B30","series-title":"Lancet Oncol","first-page":"177","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas A","year":"2015","unstructured":"Thomas A, Rajan A, Berman A,  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015;16:177\u2013186."},{"key":"B31","series-title":"J Thorac Oncol","first-page":"S313","article-title":"Evaluation of a modified dosing regimen (2-weeks on\/1-week off) of sunitinib as part of a phase II trial in thymic carcinoma","volume":"12","author":"Rajan A","year":"2017","unstructured":"Rajan A, Kim C, Guha U,  Evaluation of a modified dosing regimen (2-weeks on\/1-week off) of sunitinib as part of a phase II trial in thymic carcinoma. J Thorac Oncol 2017;12:S313\u2013314."},{"key":"B32","series-title":"J Thorac Oncol","first-page":"S346","article-title":"Phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC Trial)","volume":"13","author":"Kim SH","year":"2018","unstructured":"Kim SH, Kim YJ, Ock C,  Phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC Trial). J Thorac Oncol 2018;13:S346\u2013347."},{"key":"B33","series-title":"Lancet Oncol","first-page":"843","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato J","year":"2020","unstructured":"Sato J, Satouchi M, Itoh S,  Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 2020;21:843\u2013850."},{"key":"B34","series-title":"Lung Cancer","first-page":"107557.","article-title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial","volume":"191","author":"Niho S","year":"2024","unstructured":"Niho S, Sato J, Satouchi M,  Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial. Lung Cancer 2024;191:107557."},{"key":"B35","series-title":"J Thorac Dis","first-page":"S1509","article-title":"Thymic tumors and immune checkpoint inhibitors","volume":"10","author":"Yokoyama S","year":"2018","unstructured":"Yokoyama S, Miyoshi H. Thymic tumors and immune checkpoint inhibitors. J Thorac Dis 2018;10:S1509\u20131515."},{"key":"B36","series-title":"Lancet Oncol","first-page":"347","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone G","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J,  Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018;19:347\u2013355."},{"key":"B37","series-title":"J Clin Oncol","first-page":"2162","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho J","year":"2019","unstructured":"Cho J, Kim HS, Ku BM,  Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol 2019;37:2162\u20132170."},{"key":"B38","series-title":"Eur J Cancer","first-page":"78","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya Y","year":"2019","unstructured":"Katsuya Y, Horinouchi H, Seto T,  Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 2019;113:78\u201386."},{"key":"B39","series-title":"ESMO Open","first-page":"101576.","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard N","year":"2023","unstructured":"Girard N, Ponce Aix S, Cedres S,  Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open 2023;8:101576."},{"key":"B40","article-title":"NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas","author":"Riely GJ","unstructured":"Riely GJ, Wood DE, Aisner DL,  NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 1.2026. Accessed November 1, 2025. Available at: https:\/\/www.nccn.org"},{"key":"B41","series-title":"Lancet Oncol","first-page":"1287","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti F","year":"2022","unstructured":"Conforti F, Zucali PA, Pala L,  Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23:1287\u20131296."},{"key":"B42","series-title":"Clin Lung Cancer","first-page":"e243","article-title":"PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients","volume":"23","author":"Remon J","year":"2022","unstructured":"Remon J, Girard N, Novello S,  PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients. Clin Lung Cancer 2022;23:e243\u2013246."},{"key":"B43","series-title":"Clin Lung Cancer","first-page":"389","article-title":"ARTEMIS: a multicenter, open-label, single-arm, phase II study to evaluate the efficacy and safety of first-line carboplatin\/paclitaxel\/lenvatinib\/pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas","volume":"25","author":"Okuma Y","year":"2024","unstructured":"Okuma Y, Nomura S, Sakakibara-Konishi J,  ARTEMIS: a multicenter, open-label, single-arm, phase II study to evaluate the efficacy and safety of first-line carboplatin\/paclitaxel\/lenvatinib\/pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas. Clin Lung Cancer 2024;25:389\u2013394."},{"key":"B44","series-title":"Mediastinum","first-page":"AB016","article-title":"Phase 2 clinical trial of PT-112 in patients with thymic epithelial tumors","volume":"7","author":"McAdams M","year":"2023","unstructured":"McAdams M, Swift S, Donahue RN,  Phase 2 clinical trial of PT-112 in patients with thymic epithelial tumors. Mediastinum 2023;7: Abstract AB016."},{"key":"B45","series-title":"Clin Lung Cancer","first-page":"165","article-title":"Phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma or thymic carcinoma","volume":"26","author":"Marks JA","year":"2025","unstructured":"Marks JA, Ahn J, Reuss JE,  Phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma or thymic carcinoma. Clin Lung Cancer 2025;26:165\u2013167."},{"key":"B46","series-title":"J Thorac Oncol","first-page":"626","article-title":"Postoperative radiation therapy for thymic carcinoma: an analysis of the International Thymic Malignancy Interest Group\/European Society of Thoracic Surgeons database","volume":"19","author":"Rimner A","year":"2024","unstructured":"Rimner A, Ahmad U, Lobaugh SM,  Postoperative radiation therapy for thymic carcinoma: an analysis of the International Thymic Malignancy Interest Group\/European Society of Thoracic Surgeons database. J Thorac Oncol 2024;19:626\u2013635."},{"key":"B47","series-title":"J Thorac Oncol","first-page":"677","article-title":"Postoperative radiotherapy for completely resected Masaoka\/Masaoka-Koga stage II\/III thymoma improves overall survival: an updated meta-analysis of 4746 patients","volume":"16","author":"Tateishi Y","year":"2021","unstructured":"Tateishi Y, Horita N, Namkoong H,  Postoperative radiotherapy for completely resected Masaoka\/Masaoka-Koga stage II\/III thymoma improves overall survival: an updated meta-analysis of 4746 patients. J Thorac Oncol 2021;16:677\u2013685."},{"key":"B48","series-title":"Cancer","first-page":"1008","article-title":"Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database study","volume":"121","author":"Omasa M","year":"2015","unstructured":"Omasa M, Date H, Sozu T,  Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database study. Cancer 2015;121:1008\u20131016."},{"key":"B49","series-title":"Clin Lung Cancer","first-page":"469","article-title":"RADIORYTHMIC: phase III, opened, randomized study of postoperative radiotherapy versus surveillance in stage IIb\/III of Masaoka Koga thymoma after complete surgical resection","volume":"22","author":"Basse C","year":"2021","unstructured":"Basse C, Botticella A, Molina TJ,  RADIORYTHMIC: phase III, opened, randomized study of postoperative radiotherapy versus surveillance in stage IIb\/III of Masaoka Koga thymoma after complete surgical resection. Clin Lung Cancer 2021;22:469\u2013472."},{"key":"B50","series-title":"J Thorac Oncol","first-page":"1095","article-title":"Recommendations for post-operative radiotherapy after complete resection of thymoma-a French DELPHI consensus initiative","volume":"19","author":"Basse C","year":"2024","unstructured":"Basse C, Khalifa J, Thillays F,  Recommendations for post-operative radiotherapy after complete resection of thymoma-a French DELPHI consensus initiative. J Thorac Oncol 2024;19:1095\u20131107."},{"key":"B51","series-title":"JAMA Oncol","first-page":"971","article-title":"American Radium Society appropriate use criteria for radiation therapy in the multidisciplinary management of thymic carcinoma","volume":"9","author":"Chun SG","year":"2023","unstructured":"Chun SG, Rimner A, Amini A,  American Radium Society appropriate use criteria for radiation therapy in the multidisciplinary management of thymic carcinoma. JAMA Oncol 2023;9:971\u2013980."},{"key":"B52","series-title":"Acta Oncol","first-page":"1060","article-title":"Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies","volume":"56","author":"Vogel J","year":"2017","unstructured":"Vogel J, Lin L, Simone CB, Berman AT. Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies. Acta Oncol 2017;56:1060\u20131064."},{"key":"B53","series-title":"J Thorac Oncol","first-page":"S119.","article-title":"Treatment planning for pleural Imrt (Imprint)","volume":"14(Suppl)","author":"Rimner A","year":"2019","unstructured":"Rimner A. Treatment planning for pleural Imrt (Imprint). J Thorac Oncol 2019;14(Suppl):S119."},{"key":"B54","series-title":"Radiat Med","first-page":"399","article-title":"The role of low-dose hemithoracic radiotherapy for thoracic dissemination of thymoma","volume":"15","author":"Yoshida H","year":"1997","unstructured":"Yoshida H, Uematsu M, Itami J,  The role of low-dose hemithoracic radiotherapy for thoracic dissemination of thymoma. Radiat Med 1997;15:399\u2013403."},{"key":"B55","series-title":"J Clin Oncol","first-page":"TPS8616","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies","volume":"41(Suppl)","author":"Rimner A","year":"2023","unstructured":"Rimner A, Huang J, Pagano A,  Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies. J Clin Oncol 2023;41(Suppl):Abstract TPS8616."},{"key":"B56","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies","volume":"43(Suppl)","author":"Rimner A","year":"2023","unstructured":"Rimner A, Huang J, Pagano A,  Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies. J Clin Oncol 2023;43(Suppl):Abstract TPS8616."},{"key":"B57","series-title":"Sci Rep","first-page":"13549.","article-title":"Prospective study of stereotactic body radiation therapy for thymoma and thymic carcinoma: therapeutic effect and toxicity assessment","volume":"7","author":"Hao XJ","year":"2017","unstructured":"Hao XJ, Peng B, Zhou Z, Yang XQ. Prospective study of stereotactic body radiation therapy for thymoma and thymic carcinoma: therapeutic effect and toxicity assessment. Sci Rep 2017;7:13549."},{"key":"B58","series-title":"J Thorac Dis","first-page":"6373","article-title":"Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients","volume":"13","author":"Pasquini G","year":"2021","unstructured":"Pasquini G, Menichelli C, Pastore G,  Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients. J Thorac Dis 2021;13:6373\u20136380."},{"key":"B59","series-title":"Cureus","first-page":"e1056","article-title":"Thymic carcinoma treated by CyberKnife stereotactic body radiotherapy","volume":"9","author":"Harada Y","year":"2017","unstructured":"Harada Y, Miyazaki S. Thymic carcinoma treated by CyberKnife stereotactic body radiotherapy. Cureus 2017;9:e1056."},{"key":"B60","series-title":"JTO Clin Res Rep","first-page":"100440","article-title":"A phase 1 safety study of avelumab plus stereotactic body radiation therapy in malignant pleural mesothelioma","volume":"4","author":"Rimner A","year":"2023","unstructured":"Rimner A, Adusumilli PS, Offin MD,  A phase 1 safety study of avelumab plus stereotactic body radiation therapy in malignant pleural mesothelioma. JTO Clin Res Rep 2023;4:100440."},{"key":"B61","series-title":"J Thorac Cardiovasc Surg","first-page":"543","article-title":"Chemotherapy and operation for invasive thymoma","volume":"106","author":"Rea F","year":"1993","unstructured":"Rea F, Sartori F, Loy M,  Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993;106:543\u2013549."},{"key":"B62","series-title":"Ann Oncol","first-page":"429","article-title":"Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients","volume":"4","author":"Berruti A","year":"1993","unstructured":"Berruti A, Borasio P, Roncari A,  Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol 1993;4:429\u2013431."},{"key":"B63","series-title":"Cancer","first-page":"706","article-title":"Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma","volume":"68","author":"Macchiarini P","year":"1991","unstructured":"Macchiarini P, Chella A, Ducci F,  Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 1991;68:706\u2013713."},{"key":"B64","series-title":"J Thorac Oncol","first-page":"1070","article-title":"STYLE (NCT03449173): a phase 2 trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines","volume":"18","author":"Proto C","year":"2023","unstructured":"Proto C, Manglaviti S, Lo Russo G,  STYLE (NCT03449173): a phase 2 trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines. J Thorac Oncol 2023;18:1070\u20131081."},{"key":"B1","series-title":"Front Oncol","first-page":"1308989.","article-title":"Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019","volume":"13","author":"Gerber TS","year":"2023","unstructured":"Gerber TS, Strobl S, Marx A,  Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019. Front Oncol 2023;13:1308989."},{"key":"B2","series-title":"Chest","first-page":"2893","article-title":"Tumors of the mediastinum","volume":"128","author":"Duwe BV","year":"2005","unstructured":"Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest 2005;128:2893\u20132909."},{"key":"B3","series-title":"Ann Thorac Surg","first-page":"975","article-title":"The Society of Thoracic Surgeons expert consensus document on the surgical management of thymomas","volume":"118","author":"Liou DZ","year":"2024","unstructured":"Liou DZ, Berry MF, Brown LM,  The Society of Thoracic Surgeons expert consensus document on the surgical management of thymomas. Ann Thorac Surg 2024;118:975\u20131004."},{"key":"B4","series-title":"Ann Cardiothorac Surg","first-page":"1","article-title":"Minimally invasive versus open thymectomy: a systematic review of surgical techniques, patient demographics, and perioperative outcomes","volume":"5","author":"Hess NR","year":"2016","unstructured":"Hess NR, Sarkaria IS, Pennathur A,  Minimally invasive versus open thymectomy: a systematic review of surgical techniques, patient demographics, and perioperative outcomes. Ann Cardiothorac Surg 2016;5:1\u20139."},{"key":"B5","series-title":"J Thorac Cardiovasc Surg","first-page":"555","article-title":"A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma","volume":"160","author":"Yang CJ","year":"2020","unstructured":"Yang CJ, Hurd J, Shah SA,  A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma. J Thorac Cardiovasc Surg 2020;160:555\u2013567.e15."},{"key":"B6","series-title":"Thorac Cancer","first-page":"151","article-title":"Robot-assisted thoracic surgery versus video-assisted thoracic surgery for treatment of patients with thymoma: a systematic review and meta-analysis","volume":"13","author":"Shen C","year":"2022","unstructured":"Shen C, Li J, Li J, Che G. Robot-assisted thoracic surgery versus video-assisted thoracic surgery for treatment of patients with thymoma: a systematic review and meta-analysis. Thorac Cancer 2022;13:151\u2013161."},{"key":"B7","series-title":"J Clin Med","article-title":"Robotic vs. transsternal thymectomy: a single center experience over 10 years","volume":"10","author":"Azenha LF","year":"2021","unstructured":"Azenha LF, Deckarm R, Minervini F,  Robotic vs. transsternal thymectomy: a single center experience over 10 years. J Clin Med 2021;10:4991."},{"key":"B8","series-title":"Eur J Cardiothorac Surg","first-page":"i34","article-title":"Subxiphoid approach for robotic single-site-assisted thymectomy","volume":"58","author":"Park SY","year":"2020","unstructured":"Park SY, Han KN, Hong JI,  Subxiphoid approach for robotic single-site-assisted thymectomy. Eur J Cardiothorac Surg 2020;58:i34\u201338."},{"key":"B9","series-title":"Eur J Cardiothorac Surg","article-title":"Initial experience with the da Vinci single-port system in patients with an anterior mediastinal mass","volume":"66","author":"Kim IH","year":"2024","unstructured":"Kim IH, Kim YH, Yun JK, Kim HR. Initial experience with the da Vinci single-port system in patients with an anterior mediastinal mass. Eur J Cardiothorac Surg 2024;66:ezae325."},{"key":"B10","series-title":"Surg Endosc","first-page":"4814","article-title":"Da Vinci single-port robotic system current application and future perspective in general surgery: a scoping review","volume":"38","author":"Celotto F","year":"2024","unstructured":"Celotto F, Ramacciotti N, Mangano A,  Da Vinci single-port robotic system current application and future perspective in general surgery: a scoping review. Surg Endosc 2024;38:4814\u20134830."},{"key":"B11","series-title":"Ann Cardiothorac Surg","first-page":"110","article-title":"Biportal robotic surgery for anterior mediastinal mass","volume":"12","author":"Hong JI","year":"2023","unstructured":"Hong JI, Lee JH, Kim HK. Biportal robotic surgery for anterior mediastinal mass. Ann Cardiothorac Surg 2023;12:110\u2013116."},{"key":"B12","series-title":"Mediastinum","first-page":"14.","article-title":"The role of surgery in the management of locally advanced and metastatic thymoma: a narrative review","volume":"5","author":"Wagner C","year":"2021","unstructured":"Wagner C, Wakeam E, Keshavjee S. The role of surgery in the management of locally advanced and metastatic thymoma: a narrative review. Mediastinum 2021;5:14."},{"key":"B13","series-title":"Eur J Cardiothorac Surg","first-page":"346","article-title":"Surgical therapy of thymic tumours with pleural involvement: an ESTS Thymic Working Group Project","volume":"52","author":"Moser B","year":"2017","unstructured":"Moser B, Fadel E, Fabre D,  Surgical therapy of thymic tumours with pleural involvement: an ESTS Thymic Working Group Project. Eur J Cardiothorac Surg 2017;52:346\u2013355."},{"key":"B14","series-title":"J Surg Oncol","first-page":"604","article-title":"Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease","volume":"128","author":"Miller DL","year":"2023","unstructured":"Miller DL, Parks CS, Ange B,  Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease. J Surg Oncol 2023;128:604\u2013611."},{"key":"B15","series-title":"Ann Thorac Surg","first-page":"748","article-title":"A meta-analysis of surgical versus nonsurgical management of recurrent thymoma","volume":"98","author":"Hamaji M","year":"2014","unstructured":"Hamaji M, Ali SO, Burt BM. A meta-analysis of surgical versus nonsurgical management of recurrent thymoma. Ann Thorac Surg 2014;98:748\u2013755."},{"key":"B16","series-title":"Lung Cancer","first-page":"107214","article-title":"Unradical surgery for locally-advanced thymoma: is it time to evolve perspectives?","volume":"180","author":"Mastromarino MG","year":"2023","unstructured":"Mastromarino MG, Bacchin D, Aprile V,  Unradical surgery for locally-advanced thymoma: is it time to evolve perspectives? Lung Cancer 2023;180:107214."},{"key":"B17","series-title":"Thorac Cardiovasc Surg","first-page":"440","article-title":"Debulking surgery plus radiation: treatment choice for unresectable stage III thymic carcinoma","volume":"68","author":"Zhai Y","year":"2020","unstructured":"Zhai Y, Hui Z, Gao Y,  Debulking surgery plus radiation: treatment choice for unresectable stage III thymic carcinoma. Thorac Cardiovasc Surg 2020;68:440\u2013445."},{"key":"B18","series-title":"Sci Rep","first-page":"1735.","article-title":"Impact of definitive radiotherapy and surgical debulking on treatment outcome and prognosis for locally advanced Masaoka-Koga stage III thymoma","volume":"10","author":"Fan C","year":"2020","unstructured":"Fan C, Ge H, Zhang S,  Impact of definitive radiotherapy and surgical debulking on treatment outcome and prognosis for locally advanced Masaoka-Koga stage III thymoma. Sci Rep 2020;10:1735."},{"key":"B19","series-title":"Cancer Cell","first-page":"244","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich M","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I,  The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018;33:244\u2013258.e10."},{"key":"B20","series-title":"Med","first-page":"100612.","article-title":"Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors","author":"Mohrmann L","year":"2025;6","unstructured":"Mohrmann L, Rostock L, Werner M,  Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. Med 2025;6:100612."},{"key":"B21","series-title":"J Clin Oncol","first-page":"814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone G","year":"1996","unstructured":"Giaccone G, Ardizzoni A, Kirkpatrick A,  Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996;14:814\u2013820."},{"key":"B22","series-title":"J Clin Oncol","first-page":"2060","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma GL","year":"2011","unstructured":"Lemma GL, Lee JW, Aisner SC,  Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011;29:2060\u20132065."},{"key":"B23","series-title":"Lung Cancer","first-page":"369","article-title":"Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report","volume":"44","author":"Kim ES","year":"2004","unstructured":"Kim ES, Putnam JB, Komaki R,  Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369\u2013379."},{"key":"B24","series-title":"Cancer","first-page":"30","article-title":"Chemotherapy for invasive thymoma. A 13-year experience","volume":"68","author":"Fornasiero A","year":"1991","unstructured":"Fornasiero A, Daniele O, Ghiotto C,  Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68:30\u201333."},{"key":"B25","series-title":"Cancer","first-page":"2010","article-title":"Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an Intergroup trial","volume":"91","author":"Loehrer PJ","year":"2001","unstructured":"Loehrer PJ, Jiroutek M, Aisner S,  Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an Intergroup trial. Cancer 2001;91:2010\u20132015."},{"key":"B26","series-title":"Ann Oncol","first-page":"817","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto C","year":"2024","unstructured":"Proto C, Ganzinelli M, Manglaviti S,  Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). Ann Oncol 2024;35:817\u2013826."},{"key":"B27","series-title":"J Clin Oncol","first-page":"1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer PJ","year":"1994","unstructured":"Loehrer PJ, Kim K, Aisner SC,  Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994;12:1164\u20131168."},{"key":"B28","series-title":"Cancer Med","first-page":"3445","article-title":"Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens","volume":"11","author":"Ma WL","year":"2022","unstructured":"Ma WL, Lin CC, Hsu FM,  Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens. Cancer Med 2022;11:3445\u20133456."},{"key":"B29","series-title":"J Thorac Oncol","first-page":"223","article-title":"A phase 2 study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21)","volume":"18","author":"Jung HA","year":"2023","unstructured":"Jung HA, Kim M, Kim HS,  A phase 2 study of palbociclib for recurrent or refractory advanced thymic epithelial tumors (KCSG LU17-21). J Thorac Oncol 2023;18:223\u2013231."},{"key":"B30","series-title":"Lancet Oncol","first-page":"177","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas A","year":"2015","unstructured":"Thomas A, Rajan A, Berman A,  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015;16:177\u2013186."},{"key":"B31","series-title":"J Thorac Oncol","first-page":"S313","article-title":"Evaluation of a modified dosing regimen (2-weeks on\/1-week off) of sunitinib as part of a phase II trial in thymic carcinoma","volume":"12","author":"Rajan A","year":"2017","unstructured":"Rajan A, Kim C, Guha U,  Evaluation of a modified dosing regimen (2-weeks on\/1-week off) of sunitinib as part of a phase II trial in thymic carcinoma. J Thorac Oncol 2017;12:S313\u2013314."},{"key":"B32","series-title":"J Thorac Oncol","first-page":"S346","article-title":"Phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC Trial)","volume":"13","author":"Kim SH","year":"2018","unstructured":"Kim SH, Kim YJ, Ock C,  Phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC Trial). J Thorac Oncol 2018;13:S346\u2013347."},{"key":"B33","series-title":"Lancet Oncol","first-page":"843","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato J","year":"2020","unstructured":"Sato J, Satouchi M, Itoh S,  Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 2020;21:843\u2013850."},{"key":"B34","series-title":"Lung Cancer","first-page":"107557.","article-title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial","volume":"191","author":"Niho S","year":"2024","unstructured":"Niho S, Sato J, Satouchi M,  Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: results from the multicenter, phase 2 REMORA trial. Lung Cancer 2024;191:107557."},{"key":"B35","series-title":"J Thorac Dis","first-page":"S1509","article-title":"Thymic tumors and immune checkpoint inhibitors","volume":"10","author":"Yokoyama S","year":"2018","unstructured":"Yokoyama S, Miyoshi H. Thymic tumors and immune checkpoint inhibitors. J Thorac Dis 2018;10:S1509\u20131515."},{"key":"B36","series-title":"Lancet Oncol","first-page":"347","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone G","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J,  Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018;19:347\u2013355."},{"key":"B37","series-title":"J Clin Oncol","first-page":"2162","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho J","year":"2019","unstructured":"Cho J, Kim HS, Ku BM,  Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol 2019;37:2162\u20132170."},{"key":"B38","series-title":"Eur J Cancer","first-page":"78","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya Y","year":"2019","unstructured":"Katsuya Y, Horinouchi H, Seto T,  Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 2019;113:78\u201386."},{"key":"B39","series-title":"ESMO Open","first-page":"101576.","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard N","year":"2023","unstructured":"Girard N, Ponce Aix S, Cedres S,  Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open 2023;8:101576."},{"key":"B40","article-title":"NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas","author":"Riely GJ","unstructured":"Riely GJ, Wood DE, Aisner DL,  NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 1.2026. Accessed November 1, 2025. Available at: https:\/\/www.nccn.org"},{"key":"B41","series-title":"Lancet Oncol","first-page":"1287","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti F","year":"2022","unstructured":"Conforti F, Zucali PA, Pala L,  Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23:1287\u20131296."},{"key":"B42","series-title":"Clin Lung Cancer","first-page":"e243","article-title":"PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients","volume":"23","author":"Remon J","year":"2022","unstructured":"Remon J, Girard N, Novello S,  PECATI: a multicentric, open-label, single-arm phase II study to evaluate the efficacy and safety of pembrolizumab and lenvatinib in pretreated B3-thymoma and thymic carcinoma patients. Clin Lung Cancer 2022;23:e243\u2013246."},{"key":"B43","series-title":"Clin Lung Cancer","first-page":"389","article-title":"ARTEMIS: a multicenter, open-label, single-arm, phase II study to evaluate the efficacy and safety of first-line carboplatin\/paclitaxel\/lenvatinib\/pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas","volume":"25","author":"Okuma Y","year":"2024","unstructured":"Okuma Y, Nomura S, Sakakibara-Konishi J,  ARTEMIS: a multicenter, open-label, single-arm, phase II study to evaluate the efficacy and safety of first-line carboplatin\/paclitaxel\/lenvatinib\/pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas. Clin Lung Cancer 2024;25:389\u2013394."},{"key":"B44","series-title":"Mediastinum","first-page":"AB016","article-title":"Phase 2 clinical trial of PT-112 in patients with thymic epithelial tumors","volume":"7","author":"McAdams M","year":"2023","unstructured":"McAdams M, Swift S, Donahue RN,  Phase 2 clinical trial of PT-112 in patients with thymic epithelial tumors. Mediastinum 2023;7: Abstract AB016."},{"key":"B45","series-title":"Clin Lung Cancer","first-page":"165","article-title":"Phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma or thymic carcinoma","volume":"26","author":"Marks JA","year":"2025","unstructured":"Marks JA, Ahn J, Reuss JE,  Phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma or thymic carcinoma. Clin Lung Cancer 2025;26:165\u2013167."},{"key":"B46","series-title":"J Thorac Oncol","first-page":"626","article-title":"Postoperative radiation therapy for thymic carcinoma: an analysis of the International Thymic Malignancy Interest Group\/European Society of Thoracic Surgeons database","volume":"19","author":"Rimner A","year":"2024","unstructured":"Rimner A, Ahmad U, Lobaugh SM,  Postoperative radiation therapy for thymic carcinoma: an analysis of the International Thymic Malignancy Interest Group\/European Society of Thoracic Surgeons database. J Thorac Oncol 2024;19:626\u2013635."},{"key":"B47","series-title":"J Thorac Oncol","first-page":"677","article-title":"Postoperative radiotherapy for completely resected Masaoka\/Masaoka-Koga stage II\/III thymoma improves overall survival: an updated meta-analysis of 4746 patients","volume":"16","author":"Tateishi Y","year":"2021","unstructured":"Tateishi Y, Horita N, Namkoong H,  Postoperative radiotherapy for completely resected Masaoka\/Masaoka-Koga stage II\/III thymoma improves overall survival: an updated meta-analysis of 4746 patients. J Thorac Oncol 2021;16:677\u2013685."},{"key":"B48","series-title":"Cancer","first-page":"1008","article-title":"Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database study","volume":"121","author":"Omasa M","year":"2015","unstructured":"Omasa M, Date H, Sozu T,  Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database study. Cancer 2015;121:1008\u20131016."},{"key":"B49","series-title":"Clin Lung Cancer","first-page":"469","article-title":"RADIORYTHMIC: phase III, opened, randomized study of postoperative radiotherapy versus surveillance in stage IIb\/III of Masaoka Koga thymoma after complete surgical resection","volume":"22","author":"Basse C","year":"2021","unstructured":"Basse C, Botticella A, Molina TJ,  RADIORYTHMIC: phase III, opened, randomized study of postoperative radiotherapy versus surveillance in stage IIb\/III of Masaoka Koga thymoma after complete surgical resection. Clin Lung Cancer 2021;22:469\u2013472."},{"key":"B50","series-title":"J Thorac Oncol","first-page":"1095","article-title":"Recommendations for post-operative radiotherapy after complete resection of thymoma-a French DELPHI consensus initiative","volume":"19","author":"Basse C","year":"2024","unstructured":"Basse C, Khalifa J, Thillays F,  Recommendations for post-operative radiotherapy after complete resection of thymoma-a French DELPHI consensus initiative. J Thorac Oncol 2024;19:1095\u20131107."},{"key":"B51","series-title":"JAMA Oncol","first-page":"971","article-title":"American Radium Society appropriate use criteria for radiation therapy in the multidisciplinary management of thymic carcinoma","volume":"9","author":"Chun SG","year":"2023","unstructured":"Chun SG, Rimner A, Amini A,  American Radium Society appropriate use criteria for radiation therapy in the multidisciplinary management of thymic carcinoma. JAMA Oncol 2023;9:971\u2013980."},{"key":"B52","series-title":"Acta Oncol","first-page":"1060","article-title":"Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies","volume":"56","author":"Vogel J","year":"2017","unstructured":"Vogel J, Lin L, Simone CB, Berman AT. Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies. Acta Oncol 2017;56:1060\u20131064."},{"key":"B53","series-title":"J Thorac Oncol","first-page":"S119.","article-title":"Treatment planning for pleural Imrt (Imprint)","volume":"14(Suppl)","author":"Rimner A","year":"2019","unstructured":"Rimner A. Treatment planning for pleural Imrt (Imprint). J Thorac Oncol 2019;14(Suppl):S119."},{"key":"B54","series-title":"Radiat Med","first-page":"399","article-title":"The role of low-dose hemithoracic radiotherapy for thoracic dissemination of thymoma","volume":"15","author":"Yoshida H","year":"1997","unstructured":"Yoshida H, Uematsu M, Itami J,  The role of low-dose hemithoracic radiotherapy for thoracic dissemination of thymoma. Radiat Med 1997;15:399\u2013403."},{"key":"B55","series-title":"J Clin Oncol","first-page":"TPS8616","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies","volume":"41(Suppl)","author":"Rimner A","year":"2023","unstructured":"Rimner A, Huang J, Pagano A,  Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies. J Clin Oncol 2023;41(Suppl):Abstract TPS8616."},{"key":"B56","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies","volume":"43(Suppl)","author":"Rimner A","year":"2023","unstructured":"Rimner A, Huang J, Pagano A,  Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies. J Clin Oncol 2023;43(Suppl):Abstract TPS8616."},{"key":"B57","series-title":"Sci Rep","first-page":"13549.","article-title":"Prospective study of stereotactic body radiation therapy for thymoma and thymic carcinoma: therapeutic effect and toxicity assessment","volume":"7","author":"Hao XJ","year":"2017","unstructured":"Hao XJ, Peng B, Zhou Z, Yang XQ. Prospective study of stereotactic body radiation therapy for thymoma and thymic carcinoma: therapeutic effect and toxicity assessment. Sci Rep 2017;7:13549."},{"key":"B58","series-title":"J Thorac Dis","first-page":"6373","article-title":"Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients","volume":"13","author":"Pasquini G","year":"2021","unstructured":"Pasquini G, Menichelli C, Pastore G,  Stereotactic body radiation therapy for the treatment of pleural metastases in patients with thymoma: a retrospective review of 22 patients. J Thorac Dis 2021;13:6373\u20136380."},{"key":"B59","series-title":"Cureus","first-page":"e1056","article-title":"Thymic carcinoma treated by CyberKnife stereotactic body radiotherapy","volume":"9","author":"Harada Y","year":"2017","unstructured":"Harada Y, Miyazaki S. Thymic carcinoma treated by CyberKnife stereotactic body radiotherapy. Cureus 2017;9:e1056."},{"key":"B60","series-title":"JTO Clin Res Rep","first-page":"100440","article-title":"A phase 1 safety study of avelumab plus stereotactic body radiation therapy in malignant pleural mesothelioma","volume":"4","author":"Rimner A","year":"2023","unstructured":"Rimner A, Adusumilli PS, Offin MD,  A phase 1 safety study of avelumab plus stereotactic body radiation therapy in malignant pleural mesothelioma. JTO Clin Res Rep 2023;4:100440."},{"key":"B61","series-title":"J Thorac Cardiovasc Surg","first-page":"543","article-title":"Chemotherapy and operation for invasive thymoma","volume":"106","author":"Rea F","year":"1993","unstructured":"Rea F, Sartori F, Loy M,  Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993;106:543\u2013549."},{"key":"B62","series-title":"Ann Oncol","first-page":"429","article-title":"Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients","volume":"4","author":"Berruti A","year":"1993","unstructured":"Berruti A, Borasio P, Roncari A,  Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann Oncol 1993;4:429\u2013431."},{"key":"B63","series-title":"Cancer","first-page":"706","article-title":"Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma","volume":"68","author":"Macchiarini P","year":"1991","unstructured":"Macchiarini P, Chella A, Ducci F,  Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 1991;68:706\u2013713."},{"key":"B64","series-title":"J Thorac Oncol","first-page":"1070","article-title":"STYLE (NCT03449173): a phase 2 trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines","volume":"18","author":"Proto C","year":"2023","unstructured":"Proto C, Manglaviti S, Lo Russo G,  STYLE (NCT03449173): a phase 2 trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines. J Thorac Oncol 2023;18:1070\u20131081."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/2\/article-e257077.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/2\/article-e257077.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/2\/article-e257077.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:46:25Z","timestamp":1770644785000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/2\/article-e257077.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":128,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7077","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}